Open AccessCOVID-19 and Cardiovascular Disease
Author(s) -
Kevin J. Clerkin,
J. Fried,
J. Raikhelkar,
Gabriel Sayer,
Jan M. Griffin,
Amirali Masoumi,
Sneha S. Jain,
Daniel Burkhoff,
Deepa Kumaraiah,
LeRoy E. Rabbani,
Allan Schwartz,
Nir Uriel
Publication year - 2020
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.120.046941
Subject(s) - medicine , covid-19 , immunosuppression , pandemic , disease , angiotensin converting enzyme 2 , angiotensin converting enzyme , coronavirus , angiotensin receptor blockers , intensive care medicine , immunology , infectious disease (medical specialty) , blood pressure
Coronavirus disease 2019 (COVID-19) is a global pandemic affecting 185 countries and >3 000 000 patients worldwide as of April 28, 2020. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2, which invades cells through the angiotensin-converting enzyme 2 receptor. Among patients with COVID-19, there is a high prevalence of cardiovascular disease, and >7% of patients experience myocardial injury from the infection (22% of critically ill patients). Although angiotensin-converting enzyme 2 serves as the portal for infection, the role of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers requires further investigation. COVID-19 poses a challenge for heart transplantation, affecting donor selection, immunosuppression, and posttransplant management. There are a number of promising therapies under active investigation to treat and prevent COVID-19.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom